Eisai Biogen's Leqembi Alzheimer's drug shows benefits over three years
The newly FDA-approved Alzheimer's treatment, Leqembi, will be prepared at Abington Neurological Associates in Abington, Pennsylvania on Tuesday, November 7,…
health care industry
A bullish bet on major banks is lost in the rotation of technology stocks
Each weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
Neuralink rival Synchron offers thought control with Apple Vision Pro
Mark uses the Vision Pro with his BCI Courtesy of Synchron Neurotechnology startup Synchron announced Tuesday that it has connected…
Pfizer (PFE) Q2 2024 Results
Kena Betancur | Corbis News | Getty Images Pfizer on Tuesday reported second-quarter revenue and adjusted earnings that beat expectations…
Merck (MRK) Q2 2024 Results
An exterior view of the entrance to Merck headquarters in Rahway, New Jersey, on February 5, 2024. Spencer Platt |…
We are encouraged by Abbott's stock performance, but discouraged by the moves at Honeywell
Every weekday, the CNBC Investment Club with Jim Cramer publishes Homestretch, a handy evening update, just in time for the…
These are the top pharmaceutical stocks selected by JPMorgan for its results
JPMorgan is eyeing some drugmakers ahead of their earnings reports as investors continue to sell shares of major technology companies.…
How to trade Abbott stock after the nearly $500 million infant formula verdict
Every weekday, the CNBC Investment Club with Jim Cramer hosts a live “Morning Meeting” broadcast at 10:20 a.m. ET. Here's…
Cut 2 stocks and buy 2 other laggards
On Monday morning, we will execute four trades. Shortly after the opening bell, we will sell 100 shares of Danaher…